HomeClinical Trials Renal Cell Carcinoma Studies

Renal Cell Carcinoma Studies

This section provides a listing of all trials that have been conducted within the SUO-CTC including trials that are in process for site selection, active patient recruitment, or closed to patient accrual.

Pending Site Selection

1. “A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (EA8143 PROSPER RCC)” N= 805 patients (Sponsor: ECOG-ACRIN)

Closed/Completed Accrual

1. “A Phase III, Multicenter, Randomized, Placebo-controlled, Double Blind Study of ATEZOLIZUMAB (Anti PD-L1 Antibody) as Adjuvant Therapy in Patients with PD-L1 Selected Renal cell carcinoma at intermediate to high risk of developing metastasis following nephrectomy” N= 1000 global accrual (Sponsor: Genentech/Roche) SUO-CTC PI – Monty Pal MD, City of Hope, Duarte CA and Rob Uzzo MD, Fox Chase Cancer Center, Philadelphia PA

Site Locations:
  • Banner MD Anderson Cancer Center
  • Carolina Urologic Research Center
  • Chesapeake Urology Research Associates
  • City of Hope National Medical Center (Main)
  • City of Hope National Medical Center (Satellite)
  • Cleveland Clinic Foundation
  • Columbia University Medical Center
  • Emory University Winship Cancer Center
  • Erlanger Health Systems
  • Fox Chase Cancer Center
  • Garden State Urology
  • Levine Cancer Institute
  • Loyola University Medical Center
  • Mayo Clinic — Rochester
  • Mayo Clinic — Scottsdale
  • MD Anderson Cancer Center
  • Moffitt Cancer Center
  • Moores Cancer Center at UC San Diego Health
  • Mount Sinai Medical Center
  • NYU Langone Medical Center
  • Ochsner Clinic
  • Oregon Health and Science University
  • Penn State Hershey Cancer Institute
  • Stony Brook University Medical Center
  • SUNY Upstate Medical University
  • The Urological Institute of N.E. New York
  • The Urology Center of Colorado
  • Tulane University
  • UCLA
  • University of California Irvine Medical Center
  • University of Chicago
  • University of Colorado
  • University of Florida
  • University of Miami
  • University of North Carolina
  • University of Oklahoma
  • University of Rochester Medical Center
  • University of Texas Southwestern
  • University of Utah; Huntsman Cancer Hospital
  • UPMC Cancer Centers
  • Urology Associates of Kingsport, P.C.
  • Vanderbilt University Medical Center
  • West Virginia University Hospitals Inc.
  • Yale School of Medicine

Closed/Completed Accrual

2. “An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT) – AGS 003-007” N= 450 global accrual (Sponsor: Argos Therapeutics) SUO-CTC PI – Brian Lane MD, Spectrum Health, and Rob Uzzo MD, Fox Chase Cancer Center, Philadelphia PA

SUO-CTC contribution:

  • 38% of Active Sites (50/130)
  • 62% of Tumor Collections (N=712/1133)
  • 61% of Patients Randomized to Treatment (N=284/462)
    • 98% (49) of sites have contributed at least two nephrectomies
    • 96% (48) have randomized at least one patient to therapy
  • Patient Accrual January 2013 thru July 2015
  • Multiple abstracts accepted for presentation

Closed/Completed Accrual

3. “Sunitinib Treatment of Renal Adjuvant Cancer(S-TRAC): A Randomized Double-Blind Phase3 Study of Adjuvant Sunitinib vs. Placebo in Subjects at High Risk of Recurrent RCC – S-TRAC” N= 720 global accrual (Sponsor: Pfizer)

SUO-CTC was a late entry to the project to add to accrual:

  • 5 SUO-CTC sites
  • 10 patients accrued
  • Patient accrual June 2010 thru February 2011